Session 1: Definition of Key Events - Last Attempt?

Portal Hypertension IV: Proceedings of the 4th Baveno International Consensus Workshop

Volumn , Issue , 2007, Pages 11-37

  Burroughts, Andrew K ^a   Calès, Paul ^b   Kravetz, David ^c,h   Riggio, Oliviero ^d   Thabut, Dominique ^e   van Buuren, Henk R ^f   Kamath, Patrick S ^g  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITÉ D'ANGERS   (France)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Mayo Clinic College of Medicine   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Baveno workshop; Clinical trials; Sclerotherapy; Variceal bleeding; Vasoactive drugs

Indexed keywords

EID: 84986596809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988831.ch2     Document Type: Chapter

References (26)

1. Cales P, Lacave N, Silvain C et al. Prospective study on the application of Baveno II criteria in patients with cirrhosis and gastrointestinal bleeding. J Hepatol. 2000;33: 738-741.
2. Burroughs AK, Patch D. Therapeutic benefit of vasoactive drugs for acute variceal bleeding: a real pharmacological effect or a side effect of definition in trials? Hepatology. 1996;222: 737-739.
3. Burroughs AK ed. Assessment of value of consensus definitions in acute variceal bleeding. Lancet. 2001;357: 1147-1148.
4. de Franchis R. Developing consensus in portal hypertension. J Hepatol. 1996;25:390-394.
5. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33: 846-852.
6. Calès P, Masliah C, Bernard B et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344: 23-28.
7. Avgerinos A, Nevens F, Raptis S, Fevery J and the ABOVE Study Group. Early administration of somatostatin and efficacy of sclerotherapy in acute esophageal variceal bleeds: the European acute bleeding esophageal variceal episodes (ABOVE) randomised trial. Lancet. 1997;350: 1495-1499.
8. Bosch J, Thabut D, Bendtsen F et al. European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127: 1123-1130.
9. Sorbi D, Gostout CJ, Peura D et al. An assessment of the management of acute bleeding varices: a multicenter prospective member-based study. Am J Gastroenterol. 2003;98: 2424-2434.
10. D'Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38: 599-612.
11. Hill SR, Carless PA, Henry DA et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2002;2: CD002042.
12. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in Critical Care Investigators, Canadian Critical Care Trials Group.NEngl J Med. 1999;340: 409-417.
13. Hochain P, Mele V, Tuil S et al. Transfusion for variceal bleeding in cirrhotic patients. Gut. 1996;38: 154.
14. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80: 800-809.
15. Pagliaro L, D'Amico G, Pasta L et al. Portal hypertension in cirrhosis: natural history. In Bosch J Groszmann RJ eds. Portal Hypertension. Pathophysiology and Treatment. Oxford: Blackwell,1994; 72-92.
16. Lebrec D, Stiegmann G. Prevention of recurrent variceal haemorrhage (secondary prophylaxis). Portal hypertension. Proceedings of the third baveno international consensus workshop. Oxford, Blackwell Science, 2001.
17. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a metaanalytic review. Hepatology. 1995;22: 332-354.
18. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38: 554-558.
19. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis:a meta-analysis. Hepatology. 1997;25: 63-70.
20. Romero G, Kravetz D, Argonz J et al. Comparative study between nadolol and 5 isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients. A randomized controlled trial. Hepatology. 2004;40 (suppl 1): 204 A.
21. Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345: 647-655.
22. Lo G-H, Chen W-C, Chen M-H et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology. 2002;123: 728-734.
23. Patch D, Sabin CA, Goulis J et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123: 1013-1019.
24. de Franchis R, Primignani M. Endoscopic treatment for portal hypertension. Sem Liver Dis. 1999;19: 439-455.
25. Stiegmann GV, Goff JS, Michaletz-Onody PA et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Eng J Med. 1992;326: 1527-1532.
26. Infante-Rivard C, Esnaola S, Villeneuve JP. Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a meta-analysis. Gastroenterology. 1989;96: 1087-1092.